Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling
Open Access
- 21 October 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (10), e13536
- https://doi.org/10.1371/journal.pone.0013536
Abstract
Ashwagandha is a popular Ayurvedic herb used in Indian traditional home medicine. It has been assigned a variety of health-promoting effects of which the mechanisms remain unknown. We previously reported the selective killing of cancer cells by leaf extract of Ashwagandha (i-Extract) and its purified component Withanone. In the present study, we investigated its mechanism by loss-of-function screening (abrogation of i-Extract induced cancer cell killing) of the cellular targets and gene pathways. Randomized ribozyme library was introduced into cancer cells prior to the treatment with i-Extract. Ribozymes were recovered from cells that survived the i-Extract treatment. Gene targets of the selected ribozymes (as predicted by database search) were analyzed by bioinformatics and pathway analyses. The targets were validated for their role in i-Extract induced selective killing of cancer cells by biochemical and molecular assays. Fifteen gene-targets were identified and were investigated for their role in specific cancer cell killing activity of i-Extract and its two major components (Withaferin A and Withanone) by undertaking the shRNA-mediated gene silencing approach. Bioinformatics on the selected gene-targets revealed the involvement of p53, apoptosis and insulin/IGF signaling pathways linked to the ROS signaling. We examined the involvement of ROS-signaling components (ROS levels, DNA damage, mitochondrial structure and membrane potential) and demonstrate that the selective killing of cancer cells is mediated by induction of oxidative stress. Ashwagandha leaf extract and Withanone cause selective killing of cancer cells by induction of ROS-signaling and hence are potential reagents that could be recruited for ROS-mediated cancer chemotherapy.Keywords
This publication has 44 references indexed in Scilit:
- Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer CellsClinical Cancer Research, 2009
- A Cancer-associated Aurora A Mutant Is Mislocalized and Misregulated Due to Loss of Interaction with TPX2Published by Elsevier BV ,2009
- Kif15 Cooperates with Eg5 to Promote Bipolar Spindle AssemblyCurrent Biology, 2009
- Redox Mechanisms Involved in the Selective Activation of Nrf2-mediated Resistance Versus p53-dependent Apoptosis in Adenocarcinoma CellsJournal of Biological Chemistry, 2009
- Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded TissuesJournal of Histochemistry & Cytochemistry, 2009
- Chromatin Immunoprecipitation on Microarray Analysis of Smad2/3 Binding Sites Reveals Roles of ETS1 and TFAP2A in Transforming Growth Factor β SignalingMolecular and Cellular Biology, 2009
- Use of A U16 snoRNA-containing Ribozyme Library to Identify Ribozyme Targets in HIV-1Molecular Therapy, 2008
- Merger of Ayurveda and Tissue Culture-Based Functional Genomics: Inspirations from Systems BiologyJournal of Translational Medicine, 2008
- Selective leukemic-cell killing by a novel functional class of thalidomide analogsBlood, 2006
- PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathwaysNucleic Acids Research, 2006